FPI-2265 is under clinical development by Fusion Pharmaceuticals and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase III drugs for ...
The capabilities are based on Miele API version 1.0.7. The official capability overview is here https://www.miele.com/developer/assets/API_V1.x.x_capabilities_by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback